1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Taiwan Bio Therapeutics Co., Ltd

Taiwan Bio Therapeutics Co., Ltd

6892.TWO
Taiwan Bio Therapeutics Co., LtdTW flagTaipei Exchange
26.85
TWD
-0.45
- -
2.52BMarket Cap

Total Valuation

Taiwan Bio Therapeutics Co., Ltd carries a market capitalization of 2.52B, placing it among publicly traded companies globally. Its enterprise value stands at 2.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.52B
Enterprise Value2.51B

Share Statistics

Taiwan Bio Therapeutics Co., Ltd currently has 84.90M shares outstanding.

Shares Outstanding84.90M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 26.43, and the price-to-book ratio stands at 4.14.

PE RatioN/A
PS Ratio26.43
PB Ratio4.14
P/TBV Ratio3.26
P/FCF Ratio-11.77
P/OCF Ratio-10.21

Enterprise Valuation

EV / Sales24.48
EV / EBITDAN/A
EV / EBITN/A
EV / FCF63.54

Financial Position

Taiwan Bio Therapeutics Co., Ltd maintains a current ratio of 8.15, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 36.66, indicating elevated leverage, while an interest coverage ratio of -64.29 demonstrates limited ability to service its debt obligations.

Current Ratio8.15
Quick Ratio6.95
Debt / Equity36.66
Debt / EBITDA-0.84
Interest Coverage-64.29

Financial Efficiency

Return on Equity (ROE)-64.71
Return on Assets (ROA)-32.51
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.97

Taxes

Income Tax25,000.00
Effective Tax RateN/A

Stock Price Statistics

Taiwan Bio Therapeutics Co., Ltd's stock has declined approximately -19.85075% over the past 52 weeks. The 50-day moving average sits at 26.48, while the 200-day moving average is 27.91.

Beta (5Y)N/A
52-Week Price Change-19.85075%
50-Day Moving Average26.48
200-Day Moving Average27.91
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Taiwan Bio Therapeutics Co., Ltd generated 102.40M in revenue and converted that into -406.29M in net income, yielding earnings per share of -4.99. EBITDA reached -394.30M, while operating income came in at -394.30M.

Revenue102.40M
Gross Profit58.30M
Operating Income-394.30M
Pretax Income-406.27M
Net Income-406.29M
EBITDA-394.30M
EBIT-394.30M
Earnings Per Share (EPS)-4.99

Balance Sheet

Taiwan Bio Therapeutics Co., Ltd holds 529.60M in cash and equivalents against 329.48M in total debt, resulting in a net debt position of -529.60M. Total book value stands at 653.61M, with working capital of 545.28M providing operational flexibility.

Cash & Cash Equivalents529.60M
Total Debt329.48M
Net Debt-529.60M
Equity (Book Value)653.61M
Book Value Per Share8.03
Working Capital545.28M

Cash Flow

Taiwan Bio Therapeutics Co., Ltd produced -265.12M in operating cash flow over the past twelve months. After subtracting -35.28M in capital expenditures, free cash flow totaled -300.40M - equivalent to -3.69 per share.

Operating Cash Flow-265.12M
Capital Expenditures-35.28M
Free Cash Flow-300.40M
FCF Per Share-3.69

Margins

Taiwan Bio Therapeutics Co., Ltd operates with a gross margin of 56.94, reflecting its pricing power and cost economics. The operating margin of -385.07 and net profit margin of -396.79 provide insight into operational efficiency.

Gross Margin56.94
Operating Margin-385.07
Pretax Margin-396.76
Profit Margin-396.79
EBITDA Margin-385.07

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-14.11
FCF Yield-8.49

Stock Splits

Taiwan Bio Therapeutics Co., Ltd's most recent stock split took place on April 27, 2023 with a 200:207 split ratio.

Last Split Date4/27/2023
Split Ratio200:207

Scores

Taiwan Bio Therapeutics Co., Ltd posts an Altman Z-Score of 3.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.48